Lazard Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Lazard Asset Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-196,730	Closed	-$1.66M	–	1171
2015 Q3	$1.66M	Sell	196,730 -76,625	-28%	-$1.3M	﹤0.01%	612
2015 Q2	$4.13M	Sell	273,355 -397,247	-59%	-$5.74M	0.01%	553
2015 Q1	$10.7M	Sell	670,602 -157,077	-19%	-$2.79M	0.02%	366
2014 Q4	$14.7M	Buy	827,679 +525,410	+174%	+$6.55M	0.03%	318
2014 Q3	$3.03M	Buy	302,269 +21,980	+8%	+$266K	0.01%	569
2014 Q2	$4.38M	Buy	280,289 +30,830	+12%	+$437K	0.01%	547
2014 Q1	$4.63M	Buy	+249,459	New	+$5M	0.01%	493

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Lazard Asset Management's PETX Position: Q4 2015 in Review

Lazard Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2015, closing a stake of 196,730 shares — an estimated $1.66M sold.

Lazard Asset Management first reported a position in PETX in Q1 2014 and held it in 7 quarters. The position peaked at $14.7M in Q4 2014. 98 funds tracked by Wall St. Rank hold PETX as of Q4 2015.

Lazard Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Lazard Asset Management sold 196,730 Aratana Therapeutics, Inc. shares in Q4 2015, an estimated $1.66M.
Lazard Asset Management first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 7 quarters.
Lazard Asset Management's Aratana Therapeutics, Inc. position peaked at $14.7M in Q4 2014.
98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2015.

Based on Lazard Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.